SBP GROUP

Stock declined over 3% today, pressured by consecutive quarterly losses. Q4 2025 and Q3 2025 both showed net losses of HKD 581m and HKD 571m respectively with net margins at -7.33%, weighing on market confidence. Despite recent catalysts including global pharma partnerships with AstraZeneca and GSK, NMPA approval for innovative hepatitis B drug IM-101, and newest joint venture in Indonesia with Tempo Scan, institutional support remains guarded. Goldman Sachs and Bank of America maintain upside targets at HKD 8.41 and HKD 6.2 respectively, yet profitability deterioration challenges higher valuations; the stock trades at PB 2.78 with market cap of HKD 9.45 billion. Morning session fell over 3.8%, afternoon recovered 0.8%. Year-to-date the stock is down 20.4%, having fallen 44.5% from 52-week high of HKD 9.12, hovering near June's 52-week low of HKD 4.19 with limited rebound room.

China Biopharmaceutical declined 1.16% to HK$5.09 today, pressured by profit-taking following recent positive announcements combined with two consecutive quarters of net losses. Q4 2025 reported operating revenue of HK$7.93 billion but net loss reached HK$581 million with EPS of -HK$0.0323. Nevertheless, the company has pushed forward multiple strategic partnerships: a COPD drug deal with AstraZeneca valued up to $1.9 billion, global respiratory collaboration with GSK, NMPA clinical trial clearance for IM-101 hepatitis B drug, and latest joint venture with Tempo Scan. Analysts responded positively, with Goldman Sachs raising its target price to HK$8.41 and Bank of America maintaining HK$6.2. From a valuation perspective, the stock has fallen 19.97% year-to-date and sits 44.19% below its 52-week high of HK$9.12, though it trades notably above its 60-day moving average of HK$4.989, suggesting relative support levels.

Sino Biopharmaceutical fell 0.77% to close at HKD 5.150, with intraday volatility reflecting market appetite for recent progress tempered by profit-taking: a high of HKD 5.240 at 09:51 morning session gave way to afternoon weakness, bottoming at HKD 5.060 before recovery. Key catalysts include NMPA clearance for IM-101 hepatitis B drug trial, NDA acceptance for TQB3454 IDH1 inhibitor in biliary cancer, and licensing agreements with AstraZeneca and GSK for global expansion. Analysts remain constructive: Bank of America reiterated buy with HKD 6.2 target, and Goldman Sachs raised target to HKD 8.41. However, the stock trades at 37x P/E despite two consecutive quarters of net losses (HKD 581m loss in Q4 2025), has retreated 19% year-to-date, and sits 43.5% below its 52-week high of HKD 9.12, raising questions about the timing of the premium valuation relative to near-term profitability headwinds.

China Biopharmaceutical declined about 3% to HKD 5.19 today, mainly driven by profit-taking after recent significant licensing agreements with AstraZeneca and GlaxoSmithKline. The TQB3454 IDH1 inhibitor NDA acceptance and TQC3721 authorization grant to AstraZeneca (valued up to USD 1.9 billion) prompted Bank of America and Goldman Sachs to raise target prices to HKD 6.2 and HKD 8.41 respectively, while Citi, BOCOM, and CMB International maintained buy ratings. However, the company reported consecutive quarterly losses (Q4 net profit at negative HKD 581 million, margin -7.33%), and the share price has tumbled 43% from its 52-week peak of HKD 9.12, down 18.4% year-to-date, though still above the 60-day moving average.

Sino Biopharmaceutical climbed 4.7% today, driven by transformative international partnerships and regulatory advances. The stock rallied to 5.27 HKD during the morning session and further surged to close at 5.36 HKD in the afternoon. Key catalysts include AstraZeneca securing development and commercialization rights for COPD candidate TQC3721 with milestone payments up to USD1.9 billion, and GlaxoSmithKline obtaining China commercialization rights for respiratory inhalers including Trelegy and Anoro; simultaneously, IDH1 inhibitor TQB3454 achieved NDA acceptance in China, reinforcing the company's oncology expansion. Institutional support strengthened with Bank of America maintaining a 6.2 HKD price target and Goldman Sachs raising its target to 8.41 HKD. From a valuation lens, the stock remains 15.88% below its year-to-date entry and 41.34% below its 52-week high of 9.12 HKD, though trading above its 60-day moving average of 5.01 HKD; however, consecutive quarterly losses with Q4 EPS of -0.0323 and a net margin of -7.33% underscore execution risks embedded in the market's monetization assumptions.